CN Patent

CN101558059B — 丙型肝炎病毒抑制剂

Assigned to Bristol Myers Squibb Co · Expires 2014-12-03 · 11y expired

What this patent protects

本公开内容涉及用于治疗丙型肝炎病毒(HCV)感染的式(I)化合物、组合物和方法。本发明还公开了含有这样的化合物的药物组合物和使用这些化合物治疗HCV感染的方法。

USPTO Abstract

本公开内容涉及用于治疗丙型肝炎病毒(HCV)感染的式(I)化合物、组合物和方法。本发明还公开了含有这样的化合物的药物组合物和使用这些化合物治疗HCV感染的方法。

Drugs covered by this patent

daclatasvir-dihydrochloride (DACLATASVIR DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN101558059B
Jurisdiction: CN
Classification: —
Expires: 2014-12-03
Drug substance claim: No
Drug product claim: No
Assignee: Bristol Myers Squibb Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.